Collectively, they demonstrated that Spry2 downregulation contributes to NSCLC tumorigenesis via ERK-dependent and ERK-independent mechanisms and implicated Spry2 as a tumor suppressor in NSCLC. This evidence concerns the gene SPRY2 and non-small cell lung carcinoma.